Increased plasma concentrations of soluble CD40 ligand in acute coronary syndrome depend on in vitro platelet activation

Clinical Chemistry

Volumn 53, Issue 7, 2007, Pages 1231-1234

  Ivandic, Boris T ^a,d   Spanuth, Eberhard ^b   Haase, Detlef ^c   Lestin, Heiko Gundmar ^c   Katus, Hugo A ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b ROCHE DIAGNOSTICS GMBH   (Germany)

^c HELIOS KLINIKEN SCHWERIN   (Germany)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; CD40 LIGAND; CITRIC ACID; DIPYRIDAMOLE; THEOPHYLLINE;

ACUTE CORONARY SYNDROME; ARTICLE; ATHEROSCLEROSIS; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; IMMUNOASSAY; INFLAMMATION; LABORATORY TEST; PLASMA; THROMBOCYTE ACTIVATION; THROMBOSIS;

ACUTE DISEASE; AGED; BETA-THROMBOGLOBULIN; BIOLOGICAL MARKERS; BLOOD SPECIMEN COLLECTION; CD40 LIGAND; CORONARY ARTERIOSCLEROSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; PLASMA; PLATELET ACTIVATION; PLATELET FACTOR 4; SOLUBILITY; SYNDROME;

EID: 34347398437     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2007.085332     Document Type: Article

References (15)

1. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998;391:591-4.
2. Henn V, Steinbach S, Buchner K, Presek P, Kroczek RA. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood 2001;98:1047-54.
3. Aukrust P, Muller F, Ueland T, Berget T, Aaser E, Brunsvig A, et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina: possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 1999;100:614-20.
4. Garlichs CD, John S, Schmeisser A, Eskafi S, Stumpf C, Karl M, et al. Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia. Circulation 2001;104:2395-400.
5. Marx N, Imhof A, Froehlich J, Siam L, Ittner J, Wierse G, et al. Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation 2003;107:1954-7.
6. Nannizzi-Alaimo L, Rubenstein MH, Alves VL, Leong GY, Phillips DR, Gold HK. Cardiopulmonary bypass induces release of soluble CD40 ligand. Circulation 2002;105:2849-54.
7. Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boersma E, Zeiher AM, et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003;348:1104-11.
8. Jaffe AS, Babuin L, Apple FS. Biomarkers in acute cardiac disease: the present and the future. J Am Coll Cardiol 2006;48:1-11.
9. Conde ID, Kleiman NS. Soluble CD40 ligand in acute coronary syndromes [Letter]. N Engl J Med 2003;348:2575-7.
10. Bereczki D, Nagy E, Pal A, Magyar MT, Balla J. Should soluble CD40 ligand be measured from serum or plasma samples [Letter]? Arterioscler Thromb Vasc Biol 2003;23:1129-30.
11. Ahn ER, Lander G, Jy W, Bidot CJ, Jimenez JJ, Horstman LL, et al. Differences of soluble CD40L in sera and plasma: implications on CD40L assay as a marker of thrombotic risk. Thromb Res 2004;114:143-8.
12. Halldorsdottir AM, Stoker J, Porche-Sorbet R, Eby CS. Soluble CD40 ligand measurement inaccuracies attributable to specimen type, processing time, and ELISA method. Clin Chem 2005;51:1054-7.
13. Weber M, Rabenau B, Stanisch M, Elsaesser A, Mitrovic V, Heeschen C, et al. Influence of sample type and storage conditions on soluble CD40 ligand assessment. Clin Chem 2006;52:888-91.
14. Kaplan KL, Owen J. Plasma levels of beta-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo. Blood 1981;57:199-202.
15. Weber M, Rabenau B, Stanisch M, Nef HM, Mollmann H, Elsaesser A, et al. Influence of sample type on soluble CD40 ligand assessment in patients with acute coronary syndromes. Thromb Res Mar 1 2007; Epub ahead of print.